Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Richard Macaulay"'
Autor:
Arnold G. Vulto, Jackie Vanderpuye-Orgle, Martin van der Graaff, Steven R. A. Simoens, Lorenzo Dagna, Richard Macaulay, Beenish Majeed, Jeffrey Lemay, Jane Hippenmeyer, Sebastian Gonzalez-McQuire
Publikováno v:
Pharmaceuticals, Vol 13, Iss 11, p 400 (2020)
Introduction: Biosimilars have the potential to enhance the sustainability of evolving health care systems. A sustainable biosimilars market requires all stakeholders to balance competition and supply chain security. However, there is significant var
Externí odkaz:
https://doaj.org/article/882c9caddb54415a8aeff683d0ad78be
Publikováno v:
ClinicoEconomics and Outcomes Research. 11:199-219
Objectives The introduction of innovative, high-cost oncology treatments, coupled with mounting budgetary pressures, necessitates value trade-offs across cancer types. Defining value is critical to informing decision-making. A cost-value analysis too
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e19b891bb957dc9a8927956ee70f92d
https://doi.org/10.2147/ceor.s177343
https://doi.org/10.2147/ceor.s177343
Autor:
Richard Macaulay, Vincent Low
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 22(1)
The National Institute for Health and Care Excellence (NICE) makes recommendations on the reimbursement of new drugs utilizing an Incremental Cost-Effectiveness Ratio (ICER) threshold range that has been in use since 2004 and has remained unchanged.T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b98818b4dd6d0ba5883c010cff316d
https://pubmed.ncbi.nlm.nih.gov/33980118
https://pubmed.ncbi.nlm.nih.gov/33980118
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:13-14
IntroductionFollowing marketing authorization in Spain, new medicines are assessed by the Inter-Ministerial Pricing Commission for Pharmaceuticals (CIPM), which provides reimbursement recommendations with a maximum ex-factory price. However, there ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc130e6023bda128bc2818aaca53310b
https://doi.org/10.1017/s0266462319001193
https://doi.org/10.1017/s0266462319001193
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:69-70
IntroductionDrug development is a risky business. Manufacturers are faced with the dilemma of whether or not to invest at any stage in the development process. Even once marketing authorization has been attained, payers are becoming increasingly dema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0a2e23c1ad73cc835db4252ae280d73
https://doi.org/10.1017/s026646231900268x
https://doi.org/10.1017/s026646231900268x
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:72-73
IntroductionThe National Institute for Health and Care Excellence (NICE) may recommend temporary funding through managed access agreements (MAAs) for oncology drugs (via the Cancer Drugs Fund [CDF]) and highly specialized therapies for rare diseases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ba1bcf41ecc2686931670a24a070285
https://doi.org/10.1017/s0266462319002769
https://doi.org/10.1017/s0266462319002769
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:28-29
IntroductionThe National Institute for Health and Care Excellence (NICE) has increasingly agreed to reimburse innovative products with high levels of uncertainty as part of managed access agreements (MAAs) while additional data are collected, through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2afd6422853d636c1dac4ca900293e8c
https://doi.org/10.1017/s0266462319001582
https://doi.org/10.1017/s0266462319001582
Autor:
George C. Wang, Richard Macaulay
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:92-93
IntroductionOrphan legislations over the past thirty years have successfully increased the number of drugs receiving marketing authorization for rare diseases. However, for a therapy to be accessible to most patients, it requires not only marketing a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ef4f472d9f433e3d8b0ce986d19fd05
https://doi.org/10.1017/s0266462319003295
https://doi.org/10.1017/s0266462319003295
Publikováno v:
Value in Health Regional Issues. 6:143-149
Background: Oncology drugs lacking supportive phase III trial data have achieved Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory approval and even European reimbursement approval where no therapeutic alternative exis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1005a43cc27e77501c7037cf3d5116e5
Autor:
Richard Macaulay, George C. Wang
Publikováno v:
International Journal of Technology Assessment in Health Care. 35:77-77
IntroductionHealth technology assessment (HTA) bodies evaluate the clinical and/or economic impact of new therapies to inform public reimbursement decision-making. This research evaluates the value for money of current or proposed fees for HTA in cou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::823d787a1cc0db98038890fc31b5b305
https://doi.org/10.1017/s0266462319002873
https://doi.org/10.1017/s0266462319002873